136 related articles for article (PubMed ID: 33380300)
1. Effects of Iron Chelation in Osteosarcoma.
Argenziano M; Di Paola A; Tortora C; Di Pinto D; Pota E; Di Martino M; Perrotta S; Rossi F; Punzo F
Curr Cancer Drug Targets; 2021; 21(5):443-455. PubMed ID: 33380300
[TBL] [Abstract][Full Text] [Related]
2. Iron chelating properties of Eltrombopag: Investigating its role in thalassemia-induced osteoporosis.
Punzo F; Tortora C; Argenziano M; Casale M; Perrotta S; Rossi F
PLoS One; 2018; 13(12):e0208102. PubMed ID: 30507954
[TBL] [Abstract][Full Text] [Related]
3. Eltrombopag inhibits the proliferation of Ewing sarcoma cells via iron chelation and impaired DNA replication.
Waters T; Goss KL; Koppenhafer SL; Terry WW; Gordon DJ
BMC Cancer; 2020 Nov; 20(1):1171. PubMed ID: 33256675
[TBL] [Abstract][Full Text] [Related]
4. Deferasirox combination with eltrombopag shows anti-myelodysplastic syndrome effects by enhancing iron deprivation-related apoptosis.
Huang L; Tian M; Liu Z; Liu C; Fu R
J Investig Med; 2022 Apr; 70(4):953-962. PubMed ID: 34921125
[TBL] [Abstract][Full Text] [Related]
5. The potential of deferasirox as a novel therapeutic modality in gastric cancer.
Choi JH; Kim JS; Won YW; Uhm J; Park BB; Lee YY
World J Surg Oncol; 2016 Mar; 14():77. PubMed ID: 26965928
[TBL] [Abstract][Full Text] [Related]
6. Eltrombopag: a powerful chelator of cellular or extracellular iron(III) alone or combined with a second chelator.
Vlachodimitropoulou E; Chen YL; Garbowski M; Koonyosying P; Psaila B; Sola-Visner M; Cooper N; Hider R; Porter J
Blood; 2017 Oct; 130(17):1923-1933. PubMed ID: 28864815
[TBL] [Abstract][Full Text] [Related]
7. The Thrombopoietin Receptor Agonist Eltrombopag Inhibits Human Cytomegalovirus Replication Via Iron Chelation.
Vogel JU; Schmidt S; Schmidt D; Rothweiler F; Koch B; Baer P; Rabenau H; Michel D; Stamminger T; Michaelis M; Cinatl J
Cells; 2019 Dec; 9(1):. PubMed ID: 31861948
[TBL] [Abstract][Full Text] [Related]
8. The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action.
Lui GY; Obeidy P; Ford SJ; Tselepis C; Sharp DM; Jansson PJ; Kalinowski DS; Kovacevic Z; Lovejoy DB; Richardson DR
Mol Pharmacol; 2013 Jan; 83(1):179-90. PubMed ID: 23074173
[TBL] [Abstract][Full Text] [Related]
9. Antiproliferative and apoptotic effects in rat and human hepatoma cell cultures of the orally active iron chelator ICL670 compared to CP20: a possible relationship with polyamine metabolism.
Lescoat G; Chantrel-Groussard K; Pasdeloup N; Nick H; Brissot P; Gaboriau F
Cell Prolif; 2007 Oct; 40(5):755-67. PubMed ID: 17877614
[TBL] [Abstract][Full Text] [Related]
10. Deferasirox, a novel oral iron chelator, shows antiproliferative activity against pancreatic cancer in vitro and in vivo.
Harima H; Kaino S; Takami T; Shinoda S; Matsumoto T; Fujisawa K; Yamamoto N; Yamasaki T; Sakaida I
BMC Cancer; 2016 Aug; 16(1):702. PubMed ID: 27582255
[TBL] [Abstract][Full Text] [Related]
11. The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1.
Ohyashiki JH; Kobayashi C; Hamamura R; Okabe S; Tauchi T; Ohyashiki K
Cancer Sci; 2009 May; 100(5):970-7. PubMed ID: 19298223
[TBL] [Abstract][Full Text] [Related]
12. Initial
Nevil G; Roth M; Gill J; Zhang W; Teicher B; Erickson SW; Gatto G; Smith M; Kolb EA; Gorlick R
Pediatr Hematol Oncol; 2021 Feb; 38(1):8-13. PubMed ID: 32804009
[TBL] [Abstract][Full Text] [Related]
13. Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging.
Messa E; Carturan S; Maffè C; Pautasso M; Bracco E; Roetto A; Messa F; Arruga F; Defilippi I; Rosso V; Zanone C; Rotolo A; Greco E; Pellegrino RM; Alberti D; Saglio G; Cilloni D
Haematologica; 2010 Aug; 95(8):1308-16. PubMed ID: 20534700
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, characterization and in vitro anticancer evaluations of two novel derivatives of deferasirox iron chelator.
Salehi S; Saljooghi ASh; Shiri A
Eur J Pharmacol; 2016 Jun; 781():209-17. PubMed ID: 27090924
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of the antitumoral activity of deferasirox, an iron chelation agent, on mantle cell lymphoma.
Vazana-Barad L; Granot G; Mor-Tzuntz R; Levi I; Dreyling M; Nathan I; Shpilberg O
Leuk Lymphoma; 2013 Apr; 54(4):851-9. PubMed ID: 23020673
[TBL] [Abstract][Full Text] [Related]
16. Iron Chelator Induces Apoptosis in Osteosarcoma Cells by Disrupting Intracellular Iron Homeostasis and Activating the MAPK Pathway.
Xue Y; Zhang G; Zhou S; Wang S; Lv H; Zhou L; Shang P
Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281233
[TBL] [Abstract][Full Text] [Related]
17. Thrombopoietin receptor-independent stimulation of hematopoietic stem cells by eltrombopag.
Kao YR; Chen J; Narayanagari SR; Todorova TI; Aivalioti MM; Ferreira M; Ramos PM; Pallaud C; Mantzaris I; Shastri A; Bussel JB; Verma A; Steidl U; Will B
Sci Transl Med; 2018 Sep; 10(458):. PubMed ID: 30209246
[TBL] [Abstract][Full Text] [Related]
18. Deferasirox (ICL670A) effectively inhibits oesophageal cancer growth in vitro and in vivo.
Ford SJ; Obeidy P; Lovejoy DB; Bedford M; Nichols L; Chadwick C; Tucker O; Lui GY; Kalinowski DS; Jansson PJ; Iqbal TH; Alderson D; Richardson DR; Tselepis C
Br J Pharmacol; 2013 Mar; 168(6):1316-28. PubMed ID: 23126308
[TBL] [Abstract][Full Text] [Related]
19. Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox.
Amano S; Kaino S; Shinoda S; Harima H; Matsumoto T; Fujisawa K; Takami T; Yamamoto N; Yamasaki T; Sakaida I
BMC Cancer; 2020 Jul; 20(1):681. PubMed ID: 32698792
[TBL] [Abstract][Full Text] [Related]
20. Deferasirox shows inhibition activity against cervical cancer in vitro and in vivo.
Zhou N; Cui Y; Zhu R; Kuang Y; Ma W; Hou J; Zhu Y; Chen S; Xu X; Tan K; Cao P; Duan X; Fan Y
Gynecol Oncol; 2022 Jul; 166(1):126-137. PubMed ID: 35688655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
